These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24074763)

  • 1. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial.
    Aitchison M; Bray CA; Van Poppel H; Sylvester R; Graham J; Innes C; McMahon L; Vasey PA
    Eur J Cancer; 2014 Jan; 50(1):70-7. PubMed ID: 24074763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
    Hong SK; Kwak C; Lee SE
    Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC).
    Passalacqua R; Caminiti C; Buti S; Porta C; Camisa R; Braglia L; Tomasello G; Vaglio A; Labianca R; Rondini E; Sabbatini R; Nastasi G; Artioli F; Prati A; Potenzoni M; Pezzuolo D; Oliva E; Alberici F; Buzio C;
    J Immunother; 2014; 37(9):440-7. PubMed ID: 25304727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
    Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
    Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    Atzpodien J; Schmitt E; Gertenbach U; Fornara P; Heynemann H; Maskow A; Ecke M; Wöltjen HH; Jentsch H; Wieland W; Wandert T; Reitz M;
    Br J Cancer; 2005 Mar; 92(5):843-6. PubMed ID: 15756254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?].
    Doehn C; Merseburger AS; Jocham D; Kuczyk MA
    Urologe A; 2007 Oct; 46(10):1371-2, 1374, 1376-8. PubMed ID: 17805507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.
    Van Poppel H; Da Pozzo L; Albrecht W; Matveev V; Bono A; Borkowski A; Colombel M; Klotz L; Skinner E; Keane T; Marreaud S; Collette S; Sylvester R
    Eur Urol; 2011 Apr; 59(4):543-52. PubMed ID: 21186077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
    Doehn Ch; Richter A; Lehmacher W; Jocham D
    Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
    Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
    Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
    Itano NB; Blute ML; Spotts B; Zincke H
    J Urol; 2000 Aug; 164(2):322-5. PubMed ID: 10893575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta].
    Schenck M; Börgermann C; Jäger T; vom Dorp F; Sperling H; Rübben H; Lümmen G
    Urologe A; 2007 May; 46(5):528-34. PubMed ID: 17356836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
    Elias L; Blumenstein BA; Kish J; Flanigan RC; Wade JL; Lowe BA; Goodwin JW; Crawford ED
    Cancer; 1996 Sep; 78(5):1085-8. PubMed ID: 8780547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma.
    Sandhu SS; Symes A; A'Hern R; Sohaib SA; Eisen T; Gore M; Christmas TJ
    BJU Int; 2005 Mar; 95(4):522-5. PubMed ID: 15705072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience.
    O'Brien MF; Rea D; Rogers E; Bredin H; Butler M; Grainger R; McDermott TE; Mullins G; O'Brien A; Twomey A; Thornhill J
    Eur Urol; 2004 May; 45(5):613-8; discussion 619. PubMed ID: 15082204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Successful treatment for renal cell carcinoma with lung metastases by interleukin-2 and interferon-alfa: a case report].
    Sakata Y; Ogura Y; Wakita T; Hayashi N; Sugimura Y
    Hinyokika Kiyo; 2003 Jul; 49(7):389-91. PubMed ID: 12968479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
    Allaf ME; Kim SE; Master V; McDermott DF; Harshman LC; Cole SM; Drake CG; Signoretti S; Akgul M; Baniak N; Li-Ning E; Palmer MB; Emamekhoo H; Adra N; Kaimakliotis H; Ged Y; Pierorazio PM; Abel EJ; Bilen MA; Ogan K; Moon HH; Ramaswamy KA; Singer EA; Mayer TM; Lohrey J; Margulis V; Gills J; Delacroix SE; Waples MJ; James AC; Wang P; Choueiri T; Michaelson MD; Kapoor A; Heng DY; Shuch B; Leibovich BC; Lara PN; Manola J; Maskens D; Battle D; Uzzo R; Bratslavsky G; Haas NB; Carducci MA
    Lancet Oncol; 2024 Aug; 25(8):1038-1052. PubMed ID: 38942046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
    Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
    Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.